Your browser doesn't support javascript.
loading
Behavioral Activation mHealth Application for Smoking Cessation: A Randomized Controlled Pilot Trial.
Heffner, Jaimee L; Serfozo, Edit; Baker, Kelsey; Gasser, Melissa; Watson, Noreen; Daughters, Stacey B; Becona, Elisardo; McClure, Jennifer B.
Afiliação
  • Heffner JL; Fred Hutchinson Cancer Center, Seattle, WA USA.
  • Serfozo E; Fred Hutchinson Cancer Center, Seattle, WA USA.
  • Baker K; Fred Hutchinson Cancer Center, Seattle, WA USA.
  • Gasser M; University of Washington, Department of Psychology, Seattle, WA USA.
  • Watson N; Fred Hutchinson Cancer Center, Seattle, WA USA.
  • Daughters SB; Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC USA.
  • Becona E; University of Santiago de Compostela, Spain.
  • McClure JB; Kaiser Permanente Washington Health Research Institute, Seattle, WA USA.
Nicotine Tob Res ; 2024 Jun 07.
Article em En | MEDLINE | ID: mdl-38845464
ABSTRACT

BACKGROUND:

Behavioral activation (BA) is an effective intervention for both depression and substance use disorders. Combining BA with a standard smoking cessation intervention may improve quit rates by addressing depressive symptoms, a key barrier to quitting. This study preliminarily evaluated the acceptability and efficacy of the BA-based Actify! mobile health application (mHealth app) for smoking cessation.

METHODS:

We conducted a pilot randomized controlled trial (n=242) comparing Actify! with the National Cancer Institute's (NCI) app for smoking cessation (QuitGuide) on acceptability (user satisfaction, app openings), smoking abstinence, and mechanisms of change (behavioral activation and depressive symptoms) at 8 weeks and 6 months post-randomization. Participants were US adults recruited online who smoked daily.

RESULTS:

Treatment satisfaction was uniformly higher in the Actify! arm. Number of app openings was similar across arms (M=34.3 openings over 8 weeks in both arms). Self-reported 30-day point prevalence abstinence (PPA) at 8 weeks was 12.6% for Actify! vs. 7.3% for QuitGuide. Differences in 30-day PPA continued through 6 months (18.5% for Actify! vs. 12.2% for QuitGuide). Changes between baseline and 8 weeks in depressive symptoms and behavioral activation favored Actify!. Planned subgroup analyses suggested greater benefit of Actify! among participants with pre-treatment mild to moderate depression symptom severity compared to those with no depression symptoms.

CONCLUSIONS:

Actify! showed considerable promise as a novel mHealth treatment, as evidenced by high usage and higher user satisfaction and quit rates than QuitGuide at both short- and long-term follow-up. The next step is to evaluate Actify! in a fully-powered efficacy trial. IMPLICATIONS Study findings demonstrate the promise of a behavioral activation (BA)-based mobile health app (Actify!) for smoking cessation as a population-level intervention that can effectively address depressive symptoms as a risk factor for worse smoking treatment outcomes. The Actify! app is the first standalone BA-based app to demonstrate potential for improved acceptability and efficacy relative to a standard care comparison app, with user satisfaction and smoking quit rates descriptively exceeding those of the National Cancer Institute's QuitGuide app.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article